Skip to main content
Clinical Trials/NCT02858518
NCT02858518
Completed
Not Applicable

Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?

Centre Hospitalier Universitaire de Saint Etienne5 sites in 1 country120 target enrollmentMarch 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Enrollment
120
Locations
5
Primary Endpoint
scale : HAS-Bled
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Atrial fibrillation (AF) is a rhythmic cardiac activity disorder disturbing hemodynamic blood flow. It is a public health problem with 600,000 to 1 million people involved in France which 2/3 are aged over 75 years. a FA untreated exposes the patient to a significant risk of embolism responsible for a rate stroke (stroke) ischemic estimated at 85%. The anticoagulant standard treatment helps prevent the occurrence of this complication.

However, oral anticoagulation also exposes patients to an increased risk of bleeding. The bleeding risk can be assessed using scales: several being proposed (HEMORR2HAGES, HAS-BLED, ATRIA and scores Shireman and Charlson ...).

moreover, in geriatric hospital care, every patient has a "standardized geriatric assessment" to assess and quantify functional capacity, autonomy, cognitive abilities, nutritional status, psychological state and its environment social.

Thus, the objective of the investigators study was to determine the frequency of each item of each bleeding risk assessment score and geriatric assessment in patients 80 and older hospitalized geriatric ward in the department and with anticoagulant.

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
December 2016
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • hospitalisation in geriatric unit
  • Atrial fibrillation treated by anticoagulant treatment (AVK or oral anticoagulation)
  • signed inform consent

Exclusion Criteria

  • estimated lifetime less than 6 months
  • under guardianship or curatorship
  • without support person

Outcomes

Primary Outcomes

scale : HAS-Bled

Time Frame: at baseline

arterial hypertension, renal function, liver function, cerebrovascular accident...

scale : shireman

Time Frame: at baseline

gender, age, hemorrhage, diabetes, anemia...

scale charlson

Time Frame: at baseline

age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer

scale : HEMORR2HAGES

Time Frame: at baseline

hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...

scale : ATRIA

Time Frame: at baseline

anemia, serious kidney diseases, hypertension, antecedent...

scale : standardised geriatric assessment

Time Frame: at baseline

comorbidities, cognition, mobility, pain, nutrition, living environment...

Secondary Outcomes

  • genotyping(at baseline)
  • Occurrence of major bleeding event or not major(at baseline and 6 months)

Study Sites (5)

Loading locations...

Similar Trials